Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review

Table 2 Meta-analyses included for induction of clinical remission in ulcerative colitis

Study	Intervention	Comparator	Follow-up	n	Induction of clinical remission, RR (95%CI) or OR (95%CI)	Quality of evidence
Chande et al[24]	MTX	Placebo	36 wk	67	RR 0.96 (0.58-1.59)1	Low
	MTX	6-MP	30 wk	26	RR 0.74 (0.43-1.29)2	Very low
	MTX	5-ASA	30 wk	20	RR 2.33 (0.66-3.64) 2	Very low
Baumgart et al[25]	Tacrolimus	Placebo	2 wk	63	OR 2.27 (0.35-14.75)3	High
Lasa et al[26]	Tacrolimus	Placebo	12 wk	127	RR 0.91 (0.82-1.00)4	High

¹Clinical remission defined as a Mayo clinic score ≤ 3 (or Mayo score of ≤ 2 without sigmoidoscopy results);

²Remission defined as prednisone stopped and Mayo Clinic Score < 7;

³Clinical remission [defined as Disease Activity Index (DAI) < 2 with no individual subscore > 1];

⁴Remission defined by individual studies by Truelove-Witts Score, Modified Clinical Activity Index, clinical variables and progression to colectomy, Colitis Activity Index, Lichtiger score, Mayo score for mucosal healing or DAI Score. 5-ASA: 5-aminosalicylic acid; 6-MP: 6-mercaptopurine; CI: Confidence interval; MTX: Methotrexate; n: Number of patients; OR: Odds ratio; RR: Risk ratio; DAI: Disease Activity Index.